Finch Therapeutics Group (FNCH) Competitors $11.95 -0.20 (-1.65%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends FNCH vs. ALGS, RAPT, MIST, SLS, CLSD, JATT, ANL, CUE, DBVT, and ZIVOShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Aligos Therapeutics (ALGS), RAPT Therapeutics (RAPT), Milestone Pharmaceuticals (MIST), SELLAS Life Sciences Group (SLS), Clearside Biomedical (CLSD), JATT Acquisition (JATT), Adlai Nortye (ANL), Cue Biopharma (CUE), DBV Technologies (DBVT), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Aligos Therapeutics RAPT Therapeutics Milestone Pharmaceuticals SELLAS Life Sciences Group Clearside Biomedical JATT Acquisition Adlai Nortye Cue Biopharma DBV Technologies ZIVO Bioscience Aligos Therapeutics (NASDAQ:ALGS) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings. Which has stronger valuation & earnings, ALGS or FNCH? Finch Therapeutics Group has lower revenue, but higher earnings than Aligos Therapeutics. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$15.53M1.95-$87.68M-$20.50-0.46Finch Therapeutics Group$110K174.90-$74.75M-$8.82-1.35 Do institutionals & insiders hold more shares of ALGS or FNCH? 60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer ALGS or FNCH? In the previous week, Aligos Therapeutics' average media sentiment score of 0.98 beat Finch Therapeutics Group's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aligos Therapeutics Positive Finch Therapeutics Group Neutral Does the MarketBeat Community favor ALGS or FNCH? Aligos Therapeutics received 16 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 65.00% of users gave Aligos Therapeutics an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote. CompanyUnderperformOutperformAligos TherapeuticsOutperform Votes2665.00% Underperform Votes1435.00% Finch Therapeutics GroupOutperform Votes1052.63% Underperform Votes947.37% Is ALGS or FNCH more profitable? Finch Therapeutics Group has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,100.48%. Finch Therapeutics Group's return on equity of -69.14% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,100.48% -110.59% -63.90% Finch Therapeutics Group N/A -69.14%-26.92% Do analysts rate ALGS or FNCH? Aligos Therapeutics presently has a consensus price target of $75.00, indicating a potential upside of 691.14%. Given Aligos Therapeutics' higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more volatility & risk, ALGS or FNCH? Aligos Therapeutics has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. SummaryAligos Therapeutics beats Finch Therapeutics Group on 9 of the 16 factors compared between the two stocks. Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.51M$3.15B$5.22B$8.51BDividend YieldN/A1.75%5.06%4.17%P/E Ratio-1.356.3392.8912.89Price / Sales174.90321.691,681.9389.91Price / CashN/A144.8633.8331.25Price / Book0.844.004.734.56Net Income-$74.75M-$42.25M$116.42M$224.58M7 Day Performance3.91%-0.25%-0.78%-0.84%1 Month Performance2.22%8.21%5.52%2.96%1 Year Performance198.95%28.26%34.10%25.23% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics GroupN/A$11.95-1.6%N/A+199.0%$19.51M$110,000.00-1.35190Gap DownALGSAligos Therapeutics4.5667 of 5 stars$9.48-0.7%$75.00+691.1%-50.1%$30.34M$15.53M-0.4690Upcoming EarningsRAPTRAPT Therapeutics3.6476 of 5 stars$2.27+1.8%$18.17+700.3%-85.4%$77.83M$1.53M-0.7380Upcoming EarningsMISTMilestone Pharmaceuticals1.8479 of 5 stars$1.48+2.8%$12.00+710.8%-47.3%$76.71M$1M-1.4530Upcoming EarningsSLSSELLAS Life Sciences Group1.4659 of 5 stars$1.17-1.7%$3.00+156.4%+21.9%$76.56M$1M-1.2716CLSDClearside Biomedical2.8077 of 5 stars$1.03+2.0%$5.17+401.6%+7.8%$75.48M$8.23M-2.0630Upcoming EarningsJATTJATT AcquisitionN/A$4.37-0.2%N/A+67.2%$75.38MN/A0.003Gap UpHigh Trading VolumeANLAdlai Nortye2.3256 of 5 stars$2.03flat$9.00+343.3%-76.1%$74.91M$5M0.00127Gap UpCUECue Biopharma4.2787 of 5 stars$1.49-2.0%$5.00+235.6%-39.2%$73.94M$5.49M-1.5460Gap UpDBVTDBV Technologies3.1371 of 5 stars$0.78+2.6%$6.00+669.2%-62.1%$73.46M$15.73M-0.85106Gap UpZIVOZIVO BioscienceN/A$19.47-0.2%N/A+767.1%$69.15M$30,000.00-3.7010Gap Down Related Companies and Tools Related Companies ALGS Alternatives RAPT Alternatives MIST Alternatives SLS Alternatives CLSD Alternatives JATT Alternatives ANL Alternatives CUE Alternatives DBVT Alternatives ZIVO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FNCH) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FNCH Stock Alerts